C1-esterase inhibitor

Generic name
C1-esterase inhibitor
Brand name
ATC Code
B02AC01
Compare …

C1-esterase inhibitor

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Treatment of angio-oedema attacks
  • Intravenous
    • ≥ 2 years and 10 up to 25 kg
      • 500 IU/dose, as required second dose after 60 minutes.
    • ≥ 2 years and ≥ 25 kg
      • 1.000 IU/dose, as required second dose after 60 minutes.
Routine prevention of angio-oedema episodes
  • Intravenous
    • 6 years up to 12 years
      • 500 IU/dose every 3-4 days.

      • Adjust the dose and dosing interval to the individual response.
Pre-procedural prevention of angio-oedema attacks
  • Intravenous
    • ≥ 12 years
      • Within 24 hours before the procedure: 1.000 IU/dose, once only.
    • 2 years up to 12 years and 10 up to 25 kg
      • Within 24 hours before the procedure: 500 IU/dose, once only.
    • 2 years up to 12 years and ≥ 25 kg
      • Within 24 hours before the procedure: 1.000 IU/dose, once only.
    • ≥ 12 years
      [3]
      • Within 24 hours before the procedure: 1.000 IU/dose, once only.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Thrombotic incidents have been reported when administering high doses (off-label) to neonates and very young patients to prevent capillary leakage syndrome after bypass operations; monitor the patient extra carefully if there are risk factors for thrombotic incidents.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. Sanquin, SPC Cetor (RVG 19303), www.cbg-meb.nl, Geraadpleegd 26 mei 2010, http://db.cbg-meb.nl/IB-teksten/h19303.pdf
  3. Shire Services BVBA, SmPC Cinryze (EU/1/11/688/001) 30-03-2017, www.ema.europa.eu

Changes

Therapeutic Drug Monitoring


Overdose